北陆药业 reported revenue of ¥0.67B for the period ended 2026-06-30, +15.3% year on year. Net income was ¥0.09B, a 12.6% net margin on a 43.9% gross margin. The largest revenue line is 对比剂 at 60% of the total. Free cash flow for the period was ¥-0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.67B | +15.3% |
| Gross profit | ¥0.30B | — |
| Operating income | ¥0.10B | — |
| Net income | ¥0.09B | +216.2% |
| Gross margin | 43.9% | Net margin 12.6% |
| Revenue Q/Q | +10.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 对比剂 | ¥0.41B | 60.3% |
| 原料药 | ¥0.10B | 14.5% |
| 中成药 | ¥0.10B | 14.3% |
| 其他主营业务 | ¥0.07B | 9.7% |
| 其他(补充) | ¥0.01B | 1.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.38B | 56.1% |
| R&D | ¥0.03B | 4.5% |
| SG&A | ¥0.16B | 24.2% |
| Tax & other | ¥0.02B | 2.5% |
| Item | Amount |
|---|---|
| Total assets | ¥3.60B |
| Total liabilities | ¥0.94B |
| Shareholders' equity | ¥2.66B |
| Equity / assets | 73.8% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.01B |
| Cash conversion (OCF / net income) | 157% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
网宿科技 ・ 中元股份 ・ 硅宝科技 ・ ST银江 ・ 大禹节水 ・ 吉峰科技 ・ 机器人 ・ 华星创业 ・ 红日药业 ・ ST华谊 ・ 阳普医疗 ・ 宝通科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies